Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Depreciation and Depletion: 2016-2023

Historic Depreciation and Depletion for Tg Therapeutics (TGTX) over the last 8 years, with Sep 2023 value amounting to $73,000.

  • Tg Therapeutics' Depreciation and Depletion fell 3.95% to $73,000 in Q3 2023 from the same period last year, while for Sep 2023 it was $246,000, marking a year-over-year decrease of 20.65%. This contributed to the annual value of $303,000 for FY2022, which is 7.45% up from last year.
  • As of Q3 2023, Tg Therapeutics' Depreciation and Depletion stood at $73,000, which was up 128.12% from $32,000 recorded in Q2 2023.
  • Tg Therapeutics' Depreciation and Depletion's 5-year high stood at $80,000 during Q4 2021, with a 5-year trough of $23,000 in Q1 2019.
  • In the last 3 years, Tg Therapeutics' Depreciation and Depletion had a median value of $73,000 in 2023 and averaged $68,909.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first spiked by 97.06% in 2021, then slumped by 58.97% in 2023.
  • Tg Therapeutics' Depreciation and Depletion (Quarterly) stood at $28,000 in 2019, then soared by 89.29% to $53,000 in 2020, then soared by 50.94% to $80,000 in 2021, then dropped by 8.75% to $73,000 in 2022, then fell by 3.95% to $73,000 in 2023.
  • Its Depreciation and Depletion was $73,000 in Q3 2023, compared to $32,000 in Q2 2023 and $68,000 in Q1 2023.